Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00036062 | A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury | PHASE1 | COMPLETED | 600 | — | — | Aug 1, 2001 | Dec 1, 2002 | Jul 19, 2006 | 110 | United States, Australia +4 |
| Name | Type | Description |
|---|---|---|
| Sivelestat | DRUG | - |
Inclusion Criteria * show evidence of acute lung injury * be on mechanical ventilation Exclusion Criteria * have undergone certain organ transplants * have severe underlying medical problems * be unlikely to survive * be pregnant or breast-feeding